Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

Summary

This is a multicenter, randomized, double-blind study to evaluate the efficacy and safety of TRM-201 (rofecoxib) versus Placebo in the treatment of patients with hemophilic arthropathy (HA) over a 12-week period (Part I) that is followed by a year-long (52 week) open-label extension (Part II) to further evaluate the safety and maintenance of efficacy of TRM-201.

Timeline

Start

2021-06-02

Primary completion

2022-09-28

Completion

2022-09-28

Drugs

Indications